News

News 19.05.2026 Schlieren/Zurich, Switzerland, May 19, 2026 - Mabylon AG, a leader in the discovery and development of human-derived, half-life extended multi-specific antibodies, today reported preliminary positive Phase Ia data demonstrating a favorable safety profile of its lead candidate MY006 in an ongoing first-in-human trial. Mabylon also announced the initiation of dosing...

News 15.05.2026 CUTISS has been granted a new U.S. patent. It covers automated methods and systems for producing skin grafts, including the separation of skin layers and the isolation of key cell types from a skin biopsy. The patented invention relates to a broader automated workflow for skin graft production, in which a...

News 13.05.2026 ANDOVER, Mass.--(BUSINESS WIRE)--Aras, a leading provider of digital thread solutions for product lifecycle management (PLM) and engineering AI, today announced that Lightium, a Switzerland-based startup specializing in photonic integrated circuits (PICs), has selected Aras Innovator® to establish a connected foundation for managing the complexity of its photonic chip development. Lightium selected Aras Innovator...

News 13.05.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate...

News 08.05.2026 CAMBRIDGE, Mass., May 7, 2026 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to RPTR-1-201 for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic triple-negative breast...